IMCR241220C45000
- 2.55
- 0.000.00%
Immunocore Newsroom
Immunocore Enrolls First Patient in Phase 3 Uveal Melanoma Trial
Express News | Eortc and Immunocore Announce Enrolment of First Patient Onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma
Express News | Immunocore Announces Reimbursement Agreement in England for Kimmtrak▼ for the Treatment of Hla-a*02:01-Positive Adults With Unresectable or Metastatic Uveal Melanoma
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $74
Is Immunocore Holdings Plc (IMCR) the Best Immunotherapy Stock to Buy Now?
BioPharma Credit Receives Full Prepayment of Term Loan to Immunocore
Immunocore Hldgs Analyst Ratings
Mizuho Securities Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $38
Immunocore Downgraded to Neutral From Outperform at Mizuho
Express News | Immunocore : Mizuho Cuts to Neutral From Outperform
Immunocore Holdings Prepares Early Loan Agreement Termination
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
Immunocore to Present at Upcoming Investor Conferences
Morgan Stanley Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $74
Oppenheimer Trims Immunocore Price Target to $88 From $89, Maintains Outperform Rating